I’m not proud of it, but I’m the resident cynic amongst the editorial staff here at Budding Trends when it comes to federal marijuana reform. And after all, someone has to temper the frivolous whims of others. But we’re coming off the holiday season where I told two growing children that if they did not
FDA warning letters are nothing new in the cannabis industry. In fact, we here at Budding Trends have covered this topic a number of times (here, here, and here). Not resigned to playing the hits, however, the FDA issued a new set of warning letters on November 21 that may signal
When you start a Cannabis Industry team at a law firm based in the Southeastern United States, you get a sense of what Noah must have felt like when he was telling people it was about to rain.
But it did start to rain. And it hasn’t stopped. The Budding Trends blog is a glimpse
Cannabis operators (from marijuana to hemp-derived products such as CBD) often get the sense they are one of the central targets of the federal government’s reach. But they are not in the same league lately as the COVID-19 virus. Earlier this month, those worlds collided.
The U.S. Food and Drug Administration (FDA) and the Federal
Given the explosive growth of cannabis products and the increasing number of states that have legalized marijuana for medicinal or adult use (nearly 40 at last count), employers across the country are asking whether they can terminate an employee for a positive drug test for marijuana. What if the test shows marijuana metabolites but you